Whitelab Genomics

Whitelab Genomics' core offering is its proprietary AI platform, Catalyst™, which is available in a SaaS model. This platform leverages AI and advanced computational methods to analyze complex biological data, allowing for in-silico simulations to discover and design optimized therapeutic candidates. The technology enables the rapid exploration of numerous hypotheses simultaneously, predicting the most effective molecular designs for therapies targeting diseases like cancer and genetic disorders such as cystic fibrosis and Parkinson's. By using this computational approach, the company aims to reduce drug development timelines, mitigate risks, and lower costs associated with bringing new treatments to market. The platform assists in designing both the genetic payload and the delivery vector, critical components of gene therapies.

The company's business model is centered on collaborating with pharmaceutical companies, academic institutions, and biotechnology firms. Its client base includes organizations in Europe and the U.S. that are developing RNA, DNA, and cell-based therapies. Notable partners include Sanofi, Genethon, and Siren Biotechnology. In 2022, Whitelab Genomics was part of the Y-Combinator accelerator program and secured $10 million in a Series A funding round co-led by Omnes Capital and Debiopharm. This funding is intended to support further platform development, team expansion, and international growth, particularly in the U.S.